Expert Insights

John Strickler, MD, shares insights on the FDA’s accelerated approval of tucatinib in combination with trastuzumab for patients with RAS wild-type, HER2-positive colorectal cancer.

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.

At the 2022 San Antonio Breast Cancer Symposium, Ruth O’Regan, MD, presented updated data from the SOFT trial, investigating the predictive potential of the breast cancer index assay in determining which premenopausal patients with...

At the 2022 San Antonio Breast Cancer Symposium, Arielle Medford, MD, discusses results from the ongoing LEADER trial, investigating the efficacy of adjuvant endocrine therapy plus CDK4/6 inhibitor ribociclib for HR-positive, HER2-negative...

Shaji Kumar, MD, provides insight into approaches for treating frail and transplant-ineligible patients with multiple myeloma.

Talha Munir, MD, discusses findings from an exploratory analysis of the phase 2 CLARITY trial, which showed that early MRD clearance with ibrutinib plus venetoclax yields sustained clinical and MRD responses in relapsed/refractory CLL.

At the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, discusses the ongoing phase 2 trial evaluating the efficacy of talazoparib for patients with BRCA-mutant, HER2-negative metastatic breast cancer.

Rachna Shroff, MD, shares data from a phase 3 trial evaluating gemcitabine, cisplatin, and nab-paclitaxel for newly diagnosed, advanced biliary tract cancers.

At the 2022 San Antonio Breast Cancer Symposium, Cynthia Ma, MD, PhD, discusses the neoadjuvant therapy options available for patients with HR-positive breast cancer.

Muhammad Bilal Abid, MD, discusses findings from a retrospective cohort study that compared outcomes of patients with AML who underwent alloHSCT with younger matched unrelated donors vs older matched sibling donors, showing a reduced risk of...